AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of AFP464 in treating patients with
metastatic or refractory solid tumors that cannot be removed by surgery. Drugs used in
chemotherapy, such as AFP464, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing.